Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remazolam versus propofol for painless colorectal endoscopy
ChiCTR2000040398Phase 4Recruiting
- Sponsor
- Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
- Start
- Nov 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam mesylate, propofol and sufentanil in gastrointestinal conditions (2 arms), sponsored by Central Hospital of Enshi Tujia and Miao Autonomous Prefecture. Primary endpoints: blood pressure, oxygen saturation and 1 more. Started Nov 2020; status: recruiting.
02
Drugs
remimazolam mesylatepropofolsufentanil
03
Conditions
gastrointestinal conditions
Beyond the preview
Go deeper on ChiCTR2000040398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040398.